張紅梅 錢青
摘 要 目的:探討老年高血壓患者高同型半胱氨酸血癥(HHcy)患病情況及其與慢性腎臟病(CKD)的相關性。方法:于2017年1-6月通過問卷調查和體格檢查收集某社區(qū)596名老年高血壓患者的信息,其中男性251例,女性345例,年齡60~93歲,平均年齡(70.43±5.94)歲。應用多因素logistic回歸模型分析HHcy與CKD的相關性。結果:老年高血壓患者的CKD檢出率為25.2%,HHcy的患病率為59.40%。HHcy組患者的年齡、男性比例、血尿酸和尿素氮水平明顯大于同型半胱氨酸(Hcy)正常組(P<0.05)。校正潛在的混雜因素后,HHcy與腎功能下降及CKD成正相關,調整OR(95%CI)值分別為1.72(1.07~2.77)及4.60(1.30~16.26)。結論:老年高血壓患者HHcy患病率較高,且HHcy與CKD正相關。應在合并有HHcy的老年高血壓患者中加強CKD的篩查。
關鍵詞 老年高血壓患者;慢性腎臟?。桓咄桶腚装彼嵫Y
中圖分類號:R544.1文獻標志碼:A 文章編號:1006-1533(2019)10-0038-03
Analysis of correlation between hyperhomocysteinemia and chronic kidney disease in elderly patients with hypertension
ZHANG Hongmei, QIAN Qing(Preventive and Health Care Department of Xinzhuang Community Health Service Center of Minhang District, Shanghai 201199, China)
ABSTRACT Objective: To investigate the prevalence of hyperhomocysteinemia(HHcy) in elderly patients with hypertension and its correlation with chronic kidney disease(CKD). Methods: The information of 596 elderly patients with hypertension in a community was collected through questionnaires and physical examinations from January to June 2017, among them, there were 251 males and 345 females, and the age ranged from 60 to 93 years old, with an average age of (70.43±5.94) years old. The correlation between HHcy and CKD was analyzed by multivariate logistic regression model. Results: The detection rate of CKD in elderly hypertensive patients was 25.2%, and the prevalence of HHcy was 59.40%. The age, male proportion, blood uric acid and urea nitrogen levels in the HHcy group were significantly higher than those in the homocysteine(Hcy) normal group(P<0.05). After correcting for potential confounding factors, HHcy was positively correlated with renal dysfunction and CKD. The adjusted OR(95% CI) values were 1.72(1.07~2.77) and 4.60(1.30~16.26), respectively. Conclusion: The prevalence of HHcy is higher in elderly hypertensive patients, and HHcy is positively correlated with CKD. CKD screening should be strengthened in elderly hypertensive patients with HHcy.
KEY WORDS elderly hypertensive patient; chronic kidney disease; hyperhomocysteinemia
慢性腎臟?。–KD)已成為全球公共健康問題,是與心血管疾?。–VD)的發(fā)病率增加有關[1-2]。我國普通人群CKD的患病率已高達10.8%[3],老年高血壓患者的 CKD患病率則更高[4-6]。高血壓和糖尿病都會導致CKD的流行,但CKD增加的風險并不能完全被傳統(tǒng)的危險因素(如年齡、高血壓、糖尿病、肥胖及脂代謝紊亂等)來解釋[7]。因此,進一步尋找CKD的相關影響因素是CKD早期防治的基本措施。既往研究顯示,高同型半胱氨酸血癥(HHcy)與動脈粥樣硬化性血管疾病相關[8-9],是CVD的重要危險因素[10]。本文旨在探討老年高血壓患者中HHcy患病情況及其與CKD的相關性,為高血壓患者CKD的早期防治提供依據。
1 對象和方法
1.1 對象
以2017年1-6月在上海市閔行區(qū)莘莊社區(qū)衛(wèi)生服務中心自愿參加免費健康體檢的596名60歲及以上高血壓患者為調查對象。其中男251例,女345例,年齡60~93歲,平均年齡(70.43±5.94)歲。
1.2 方法
問卷調查內容包括性別、年齡、運動情況、既往病史(糖尿病、心肌梗死及腦梗死等)。體格檢查內容包括身高、體重、腰圍、收縮壓(SBP)和舒張壓(DBP),并計算體質指數(BMI),BMI=體重(kg)/身高(m)2。調查對象在空腹8~10 h后被抽取靜脈血和留取空腹晨尿。晨尿采用日立7180 全自動生化分析儀檢測尿微量白蛋白(乳膠增強免疫比濁法)和尿肌酐(肌氨酸氧化酶法)。血樣被用于檢測血漿同型半胱氨酸(Hcy)、血清肌酐(SCr)、尿素氮(BUN)、尿酸(UA)、空腹血糖(FPG)、三酰甘油(TG)、總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-c)、高密度脂蛋白膽固醇(HDL-c)、血紅蛋白等。采用GE LOGIQ P6型彩色超聲診斷儀進行腎臟B超檢查。
1.3 診斷標準
根據《中國高血壓防治指南2018年修訂版》[11]將Hcy≥15 μmol/L定義為HHcy。符合下列4項中至少一項被診斷為CKD:(1)蛋白尿:尿常規(guī)蛋白≥1+;(2)血尿或白細胞尿,即在光學顯微鏡下400倍視野中發(fā)現3個以上紅細胞或5個以上白細胞為陽性;(3)尿微量白蛋白/尿肌酐比值(尿ACR)>30 mg/g;(4)將估算的腎小球濾過率(eGFR)<60 ml/min/1.73 m2定義為腎功能下降(deGFR)。eGFR計算采用MDRD公式[12],eGFR(ml/min/1.73m2)=175×Scr-1.234×年齡-0.179×0.79(女性)。
1.4 統(tǒng)計學處理
2 結果
2.1 HHcy組與Hcy正常組老年高血壓患者的基本情況比較
596例老年高血壓患者的平均eGFR為(89.81±21.87)ml/min/1.73m2;HHHcy的患病率為59.40%。HHcy組患者的年齡、男性比例、腰圍、UA及BUN水平均大于Hcy正常組(P<0.05);eGFR平均水平低于Hcy組(P<0.001)。見表1。
2.2 HHcy組與Hcy正常組老年高血壓患者CKD及其主要診斷指標比較
在老年高血壓患者中檢出CKD150人,檢出率為25.2%,其中HHcy患者的CKD檢出率為28.8%,Hcy正常組患者的CKD檢出率為19.8%,差異有統(tǒng)計學意義(P=0.013)。HHcy組的deGFR、尿ACR異?;疾÷拭黠@高于Hcy正常組(P<0.05)。見表2。
2.3 HHcy與CKD相關指標的多因素Logistic回歸分析
在單變量logistic回歸分析中,HHcy與eGFR和CKD的未校正OR值分別為9.02(95%CI為2.75~29.64)和1.85(95%CI為1.23~2.80)。調整了年齡、性別、糖尿病、腦血管病、心臟疾病、腎超聲異常、吸煙、運動、腰圍、BMI、血壓、FPG、TG、TC、LDL-c、HDL-c、UA、血紅蛋白等變量后,HHcy與deGFR及CKD仍然相關。見表3。
3 討論
HHcy被認為與許多疾病相關,特別是血管鈣化、動脈粥樣硬化等心血管疾病[13]和晚期腎臟病[14]等。本次研究結果顯示,老年高血壓患者中HHcy患病率高達59.40%,遠遠高于Kong等[15]在一般人群25.0%的調查結果。應用deGFR、蛋白尿、血尿或白細胞尿、以及尿ACR異常來定義CKD,老年高血壓患者的CKD患病率為25.2%,HHcy患者中CK D的患病率明顯高于Hcy正常組。調查還顯示HHcy組的年齡、男性比例、UA、BUN水平高于Hcy組,說明男性老年患者更應注重Hcy水平的監(jiān)測,并同時定期監(jiān)測UA和BUN水平。
在老年高血壓患者中,HHcy組的deGFR、尿ACR異常及CKD的患病率明顯高于正常組。在調整了潛在混雜因素后,HHcy與deGFR及CKD獨立相關,提示在老年高血壓人群中檢測Hcy具有重要的意義。尤其對合并有HHcy的患者重點篩查CKD,做到早防早治。HHcy與CKD及蛋白尿的發(fā)生在普通人群中也存在關聯(lián)[16-17]。而本研究多因素回歸分析并沒有顯示HHcy與蛋白尿相關。
我們的研究也存在著一些不足。首先,本研究對象是60歲及以上的高血壓人群,樣本的代表性具有一定的局限性;其次,該研究采用橫斷面設計,不能解釋HHcy與CKD的因果關系。
參考文獻
[1] Nugent RA, Fathima SF, Feigl AB, et al. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health[J]. Nephron Clin Pract, 2011, 118(3): 269-277.
[2] Chen XN, Pan XX, Yu HJ, et al. Analysis of cardiovascular disease in Chinese in patients with chronic kidney disease[J]. Intern Med, 2011, 50: 1797-1801.
[3] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2112, 379(9818): 815-822.
[4] Chen J, Wildman RP, Gu D, et al. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years[J]. Kidney Int, 2005, 68(6): 2837-2845.
[5] Zhang L,.Zhang P,.Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing[J]. Am J Kidney Dis, 2008, 51(3): 373-384.
[6] 張麗紅, 于倩倩, 范偉峰, 等. 上海閔行地區(qū)城鄉(xiāng)老年人慢性腎臟病患病率及其相關因素的對比[J]. 中華腎臟病雜志, 2017, 33(5): 356-362.
[7] Chue CD, Townend JN, Steeds RP, et al. Arterial stiffness in chronic kidney disease: causes and consequences[J]. Heart, 2010, 96(11): 817-823.
[8] Welch GN, Ijoscalzo J. Homocysteine and atherothrombosis[J]. N End J Med, 1998, 338(15): 1042-1050.
[9] Elias MF, crichton GE, Abhayaratna WP. Interactions between plasma homocysteine and arterial stiffness in chronic kidney disease in community—dwelling individuals: The Maine Syracuse study[J]. J Hum Hypertens, 2015, 29(12): 726-731.
[10] Cui R, Moriyama Y, Koike KA, et a1. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study[J]. Atherosclerosis, 2008, 198(2): 412-418.
[11] 中國高血壓防治指南修訂委員會. 中國高血壓防治指南2 0 1 8年修訂版[J]. 心腦血管病防治, 2019, 19(1): 1-44.
[12] 全國e G F R課題協(xié)作組. MDRD方程在我國慢性腎臟病患者中的改良和評估[J]. 中國腎臟病雜志, 2006, 22(10): 589-595.
[13] Bostom AG, Calpenter MA, Kusek JW, et a1.Homocysteine—lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular outcome Reduction in Transplantation trial[J]. Circulation, 2011, 123(16): 1763-1770.
[14] Perna AF, Ingrosso D, Satta E, et al. Homocysteine metabolism in renal failure[J]. Curr Opin Clin Nutr Metab Care, 2004, 7: 53-57.
[15] Kong X, Ma X, Zhang C, et al. Hyperhomocysteinemia increases the risk of chronic kidney disease in a Chinese middle-aged and elderly population-based cohort[J]. Int Urol Nephrol, 2017, 49(4): 661–667.
[16] N i n o m i y a T, K i y o h a r a Y, K u b o M , e t a 1 . Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study[J]. Am J Kidney Dis, 2004, 44(3): 437-445.
[17] Mani F, Vollenweider P, Marques-Vidal PM, et a1. Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study[J]. BMc Public Health, 2011, 11: 733.